Sizing up the Oral Alternatives for MS

Sizing up the oral alternatives for MS

Two milestones were met late last month in the race to get the first oral treatment for multiple sclerosis to market: Merck KGaA submitted an NDA for its cladribine to treat relapsing-remitting MS; and Novartis AG reported Phase III data from a placebo-controlled trial of fingolimod...